TBPH · As filed with the SEC
Theravance Biopharma balance sheet, by fiscal year
The statement as Theravance Biopharma presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONSOLIDATED BALANCE SHEETS · USD
| USD | FY2025 Dec 31, 2025 | FY2024 Dec 31, 2024 | FY2023 Dec 31, 2023 | FY2022 Dec 31, 2022 |
|---|---|---|---|---|
| Current assets: | ||||
| Cash and cash equivalents | 167,806,000 | 37,797,000 | 39,545,000 | 298,172,000 |
| Short-term marketable securities | 147,551,000 | 50,553,000 | 62,881,000 | 29,312,000 |
| Receivables from collaborative arrangements | 45,539,000 | 18,440,000 | 17,474,000 | 16,785,000 |
| Receivables from milestones and royalty assets | 50,000,000 | 50,000,000 | — | — |
| Prepaid clinical and development services | — | 73,000 | 2,038,000 | 1,513,000 |
| Other prepaid and current assets | 7,564,000 | 4,204,000 | 11,603,000 | 7,682,000 |
| Total current assets | 418,460,000 | 161,067,000 | 133,541,000 | 353,464,000 |
| Long-term marketable securities | 11,128,000 | — | — | — |
| Property and equipment, net | 5,895,000 | 7,418,000 | 9,068,000 | 11,875,000 |
| Operating lease assets | 24,371,000 | 28,354,000 | 36,287,000 | 40,126,000 |
| Future contingent milestone and royalty assets | — | 144,200,000 | 194,200,000 | 194,200,000 |
| Restricted cash | 836,000 | 836,000 | 836,000 | 836,000 |
| Other assets | 24,880,000 | 12,286,000 | 8,067,000 | 6,899,000 |
| Total assets | 485,570,000 | 354,161,000 | 381,999,000 | 607,400,000 |
| Current liabilities: | ||||
| Accounts payable | 2,568,000 | 2,242,000 | 1,524,000 | 1,554,000 |
| Accrued personnel-related expenses | 12,592,000 | 7,019,000 | 6,443,000 | 10,314,000 |
| Accrued clinical and development expenses | 3,373,000 | 1,058,000 | 2,246,000 | 4,932,000 |
| Accrued general and administrative expenses | 2,052,000 | 2,987,000 | 2,900,000 | 4,020,000 |
| Operating lease liabilities | 10,945,000 | 10,712,000 | 3,923,000 | 6,753,000 |
| Deferred revenue | — | — | — | 24,000 |
| Income tax payable | 5,287,000 | 5,853,000 | — | — |
| Other accrued liabilities | 1,485,000 | 2,214,000 | 1,241,000 | 1,118,000 |
| Tenant improvement payable to sublessee | — | — | 6,490,000 | — |
| Total current liabilities | 38,302,000 | 32,085,000 | 24,767,000 | 28,715,000 |
| Long-term operating lease liabilities | 31,758,000 | 39,108,000 | 45,236,000 | 45,407,000 |
| Future royalty payment contingency | 32,795,000 | 30,334,000 | 27,788,000 | 25,438,000 |
| Long-term deferred revenue | — | — | — | 192,000 |
| Unrecognized tax benefits | — | 75,199,000 | 65,294,000 | 64,191,000 |
| Unrecognized tax benefits | 85,679,000 | — | — | — |
| Other long-term liabilities | 313,000 | 1,890,000 | 5,919,000 | 1,657,000 |
| Shareholders' Equity | ||||
| Ordinary shares, $0.00001 par value per share: 200,000 shares authorized; 51,069 and 49,471 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | 1,000 | — | — | 1,000 |
| Additional paid-in capital | 1,156,288,000 | 1,141,060,000 | 1,122,164,000 | 1,295,725,000 |
| Accumulated other comprehensive income | 61,000 | 7,000 | (65,000) | (15,000) |
| Accumulated deficit | (859,627,000) | (965,522,000) | (909,104,000) | (853,911,000) |
| Total shareholders' equity | 296,723,000 | 175,545,000 | 212,995,000 | 441,800,000 |
| Total liabilities and shareholders' equity | 485,570,000 | 354,161,000 | 381,999,000 | 607,400,000 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.